Navigation Links
Micromet, Inc. Reports Third Quarter 2008 Financial Results
Date:11/6/2008

(In thousands, except par value)

September December

30, 31,

2008 2007

(unaudited)

Assets

Current assets:

Cash and cash equivalents $15,936 $27,066

Accounts receivable 1,939 4,689

Prepaid expenses and other current

assets 1,670 2,579

Total current assets 19,545 34,334

Property and equipment, net 3,704 4,390

Goodwill 6,462 6,462

Patents, net 5,918 7,680

Other long-term assets 264 196

Restricted cash 3,169 3,190

Total assets $39,062 $56,252

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable $1,085 $2,334

Accrued expenses 5,748 4,765

Common stock warrants liability 12,733 5,219

Other liabilities 433 520

Current portion of long-term debt

obligations - 2,401

Current portion of deferred revenue 5,026 3,360

Total current liabilities 25,025 18,599

Deferred revenue, net of current portion 7,842 8,366

Other non-current liabilities
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
2. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
3. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
4. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
5. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
8. EntreMed Reports Third Quarter 2008 Financial Results
9. CV Therapeutics Reports 2008 Third Quarter Financial Results
10. Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase
11. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... , WILMINGTON, Del. and ... AZN ) and the University of Virginia (UVa) in ... strategic research collaboration to enhance development of new treatments ... focus on peripheral vascular disease (PAD). , (Logo: ...
... , , , ... for Medical Publication Professionals (ISMPP) today announced that the professional ... Meeting, which is being held in Arlington, VA, April 19-21, ... encouraging non-members to join the organization to submit an abstract ...
... and LONDON, Dec. 15 Thomson ... the first drug pipeline database to fully integrate detailed clinical ... is being provided to all Thomson Pharma customers this month. ... related clinical trial intelligence from registries, publications, press releases, conferences, ...
Cached Biology Technology:AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 2The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 3Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials 2
(Date:12/3/2014)... As part of our commitment to offering ... to announce the release of a new reader that ... workforce data that they need. The Atlas ... existing readers. Many such devices have serious shortcomings when ... Older models force users to navigate numerous complicated steps ...
(Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... Nov. 17, 2014 The Parenteral Drug Association (PDA) ... agencies will speak and at least seven more will participate ... the Omni Shoreham Hotel in Washington D.C. ... to have significant support from the regulatory agencies in ... in our effort to help advance the use ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... issue of the Journal of Integrated Pest Management ... western bean cutworm (WBC), Striacosta albicosta (Smith), ... genetically engineered corn." The Greenpeace Germany report, which was ... "surprisingly simplistic conclusion" regarding the spread of western bean ...
... of the Bulletin of the Atomic Scientists , published ... look out for in 2012 in the areas of nuclear ... made the headlines during the previous 12 months, including the ... Fukushima incident, and the state of US policy on climate ...
... New research highlights the possibility of reversing ageing in the central ... published today, 06 January, in the journal Cell Stem Cell ... decreases. This is not only true for our skin (which ... also true for other tissues in the body, including the regenerative ...
Cached Biology News:Scientists refute Greenpeace claim that genetically modified corn caused new insect pest 2The nuclear, biological and climate threat - 2011 reviewed 2The nuclear, biological and climate threat - 2011 reviewed 3Hopes for reversing age-associated effects in MS patients 2
... T2-04 is an ultra-compact pump available in single ... and ideal for use in portable air and ... this pump works well in environments where DC ... compact size are critical., Offers ultra-compact size, ...
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... Lone Wolf valve has the highest performance ... available on the market. This VSO valve ... and ensures maximum accuracy., Achieves rapid, ... and patient comfort. , Maintains ideal flow ...
Biology Products: